Hansz J
Kliniki Hematologii AM, Poznaniu.
Acta Haematol Pol. 1992;23(2 Suppl 1):38-48.
Bone marrow transplantation (BMT) is at present the only curative therapy for chronic myelogenous leukemia (CML). The outcome of this therapy is much better if marrow transplantation from HLA-matched siblings is performed within 1 year of diagnosis, in young patients and in the chronic phase of the disease. BMT from HLA-matched unrelated donors expands the application of this therapy among CML patients with no available identical siblings. Autologous bone marrow transplantation is presently considered in patients unresponsive to interferon therapy or with high risk of blastic transformation.
骨髓移植(BMT)是目前慢性粒细胞白血病(CML)唯一的治愈性疗法。如果在诊断后1年内进行来自人类白细胞抗原(HLA)匹配同胞的骨髓移植,且患者为年轻患者且处于疾病的慢性期,那么这种疗法的效果会好得多。来自HLA匹配的无关供者的骨髓移植扩大了这种疗法在没有合适同胞供者的CML患者中的应用范围。自体骨髓移植目前用于对干扰素治疗无反应或有高 blast 转化风险的患者。 (注:原文中“blastic transformation”直译为“blast转化”,可能是医学术语,具体准确含义需结合医学专业知识进一步明确,这里暂按原文翻译。)